More than a year after legal wrangling derailed a $2 billion deal to hasten development of its antibody drug conjugate (ADC) IMMU-132 (sacituzumab govitecan) for breast cancer, Immunomedics Inc. is racing toward new regulatory milestones. The company submitted updated phase II data on the ADC in metastatic triple-negative breast cancer (mTNBC) to support an ongoing FDA priority review while also reaching an accord with the agency on the design of a registration-enabling trial for the drug in HR+/HER2- metastatic breast cancer (mBC), it said.